Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors

A pediatric oncology group study

Neyssa M. Marina, Debon Cochrane, Elaine Harney, Katie Zomorodi, Susan Blaney, Naomi Winick, Mark Bernstein, Michael P. Link

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

Purpose: To determine the maximum tolerated dose and pharmacokinetics of Doxil in children with recurrent or refractory solid tumors. Doxil is pegylated doxorubicin. Experimental Design: Eligible patients were children with refractory tumors who had received cumulative anthracycline doses <300 mg/m2. Cohorts of at least three patients each received escalating doses of Doxil starting at 40 mg/m2 at 4-week intervals. If no dose-limiting toxicity occurred, dosages were escalated by increments of 10 mg/m2 in subsequent cohorts. Originally, Doxil was administered over 60 min, but significant infusion reactions prompted longer infusion times of 4 h. Patients also received premedication with dexamethasone, ranitidine, and diphenhydramine 24 h before infusion, with ranitidine continued 24 h after infusion. Periodic blood samples were collected and plasma doxorubicin concentrations were quantified to characterize the pharmacokinetics of Doxil. Results: Between January 1997 and June 2000, 22 children ages 4-21 years with refractory tumors were treated with Doxil. Most patients had received one to five prior chemotherapy regimens, and all but five had prior radiotherapy (two had no prior therapy). Doxil was escalated to a dosage of 70 mg/m2. At that level, dose-limiting mucositis was seen during the first cycle in two of six patients, thus defining dose-limiting toxicity, and in one additional patient during a subsequent cycle. Grade 4 neutropenia lasting less than 7 days was documented in two of six patients. The dose-limiting toxicity among two of six patients at 70 mg/m2 was grade 3 mucositis during the first cycle of therapy. Painful desquamating dermatitis of the hands and feet, palmar-plantar erythrodysesthesia, occurred in six patients. In two of those patients, palmar-plantar erythrodysesthesia started as grade 1 and progressed to grade 2 during subsequent courses. Mean estimates of central volume of distribution, clearance, and elimination half-life were 1.45 liters/m2, 0.03 liter/h/m2, and 36.4 h, respectively. Conclusion: The maximum tolerated dose of Doxil administered every 4 weeks to pediatric patients was 60 mg/m2. The effect of Doxil on pediatric patients with malignancies remains to be determined and should be studied in pediatric Phase II trials.

Original languageEnglish (US)
Pages (from-to)413-418
Number of pages6
JournalClinical Cancer Research
Volume8
Issue number2
StatePublished - 2002

Fingerprint

Pharmacokinetics
Pediatrics
Neoplasms
Mucositis
Ranitidine
Maximum Tolerated Dose
Doxorubicin
liposomal doxorubicin
Diphenhydramine
Premedication
Anthracyclines
Dermatitis
Neutropenia
Dexamethasone
Half-Life
Foot
Research Design
Radiotherapy
Hand
Drug Therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors : A pediatric oncology group study. / Marina, Neyssa M.; Cochrane, Debon; Harney, Elaine; Zomorodi, Katie; Blaney, Susan; Winick, Naomi; Bernstein, Mark; Link, Michael P.

In: Clinical Cancer Research, Vol. 8, No. 2, 2002, p. 413-418.

Research output: Contribution to journalArticle

Marina, NM, Cochrane, D, Harney, E, Zomorodi, K, Blaney, S, Winick, N, Bernstein, M & Link, MP 2002, 'Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors: A pediatric oncology group study', Clinical Cancer Research, vol. 8, no. 2, pp. 413-418.
Marina, Neyssa M. ; Cochrane, Debon ; Harney, Elaine ; Zomorodi, Katie ; Blaney, Susan ; Winick, Naomi ; Bernstein, Mark ; Link, Michael P. / Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors : A pediatric oncology group study. In: Clinical Cancer Research. 2002 ; Vol. 8, No. 2. pp. 413-418.
@article{9a7f9b3f851c43da9d1417cf0d49b9d3,
title = "Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors: A pediatric oncology group study",
abstract = "Purpose: To determine the maximum tolerated dose and pharmacokinetics of Doxil in children with recurrent or refractory solid tumors. Doxil is pegylated doxorubicin. Experimental Design: Eligible patients were children with refractory tumors who had received cumulative anthracycline doses <300 mg/m2. Cohorts of at least three patients each received escalating doses of Doxil starting at 40 mg/m2 at 4-week intervals. If no dose-limiting toxicity occurred, dosages were escalated by increments of 10 mg/m2 in subsequent cohorts. Originally, Doxil was administered over 60 min, but significant infusion reactions prompted longer infusion times of 4 h. Patients also received premedication with dexamethasone, ranitidine, and diphenhydramine 24 h before infusion, with ranitidine continued 24 h after infusion. Periodic blood samples were collected and plasma doxorubicin concentrations were quantified to characterize the pharmacokinetics of Doxil. Results: Between January 1997 and June 2000, 22 children ages 4-21 years with refractory tumors were treated with Doxil. Most patients had received one to five prior chemotherapy regimens, and all but five had prior radiotherapy (two had no prior therapy). Doxil was escalated to a dosage of 70 mg/m2. At that level, dose-limiting mucositis was seen during the first cycle in two of six patients, thus defining dose-limiting toxicity, and in one additional patient during a subsequent cycle. Grade 4 neutropenia lasting less than 7 days was documented in two of six patients. The dose-limiting toxicity among two of six patients at 70 mg/m2 was grade 3 mucositis during the first cycle of therapy. Painful desquamating dermatitis of the hands and feet, palmar-plantar erythrodysesthesia, occurred in six patients. In two of those patients, palmar-plantar erythrodysesthesia started as grade 1 and progressed to grade 2 during subsequent courses. Mean estimates of central volume of distribution, clearance, and elimination half-life were 1.45 liters/m2, 0.03 liter/h/m2, and 36.4 h, respectively. Conclusion: The maximum tolerated dose of Doxil administered every 4 weeks to pediatric patients was 60 mg/m2. The effect of Doxil on pediatric patients with malignancies remains to be determined and should be studied in pediatric Phase II trials.",
author = "Marina, {Neyssa M.} and Debon Cochrane and Elaine Harney and Katie Zomorodi and Susan Blaney and Naomi Winick and Mark Bernstein and Link, {Michael P.}",
year = "2002",
language = "English (US)",
volume = "8",
pages = "413--418",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors

T2 - A pediatric oncology group study

AU - Marina, Neyssa M.

AU - Cochrane, Debon

AU - Harney, Elaine

AU - Zomorodi, Katie

AU - Blaney, Susan

AU - Winick, Naomi

AU - Bernstein, Mark

AU - Link, Michael P.

PY - 2002

Y1 - 2002

N2 - Purpose: To determine the maximum tolerated dose and pharmacokinetics of Doxil in children with recurrent or refractory solid tumors. Doxil is pegylated doxorubicin. Experimental Design: Eligible patients were children with refractory tumors who had received cumulative anthracycline doses <300 mg/m2. Cohorts of at least three patients each received escalating doses of Doxil starting at 40 mg/m2 at 4-week intervals. If no dose-limiting toxicity occurred, dosages were escalated by increments of 10 mg/m2 in subsequent cohorts. Originally, Doxil was administered over 60 min, but significant infusion reactions prompted longer infusion times of 4 h. Patients also received premedication with dexamethasone, ranitidine, and diphenhydramine 24 h before infusion, with ranitidine continued 24 h after infusion. Periodic blood samples were collected and plasma doxorubicin concentrations were quantified to characterize the pharmacokinetics of Doxil. Results: Between January 1997 and June 2000, 22 children ages 4-21 years with refractory tumors were treated with Doxil. Most patients had received one to five prior chemotherapy regimens, and all but five had prior radiotherapy (two had no prior therapy). Doxil was escalated to a dosage of 70 mg/m2. At that level, dose-limiting mucositis was seen during the first cycle in two of six patients, thus defining dose-limiting toxicity, and in one additional patient during a subsequent cycle. Grade 4 neutropenia lasting less than 7 days was documented in two of six patients. The dose-limiting toxicity among two of six patients at 70 mg/m2 was grade 3 mucositis during the first cycle of therapy. Painful desquamating dermatitis of the hands and feet, palmar-plantar erythrodysesthesia, occurred in six patients. In two of those patients, palmar-plantar erythrodysesthesia started as grade 1 and progressed to grade 2 during subsequent courses. Mean estimates of central volume of distribution, clearance, and elimination half-life were 1.45 liters/m2, 0.03 liter/h/m2, and 36.4 h, respectively. Conclusion: The maximum tolerated dose of Doxil administered every 4 weeks to pediatric patients was 60 mg/m2. The effect of Doxil on pediatric patients with malignancies remains to be determined and should be studied in pediatric Phase II trials.

AB - Purpose: To determine the maximum tolerated dose and pharmacokinetics of Doxil in children with recurrent or refractory solid tumors. Doxil is pegylated doxorubicin. Experimental Design: Eligible patients were children with refractory tumors who had received cumulative anthracycline doses <300 mg/m2. Cohorts of at least three patients each received escalating doses of Doxil starting at 40 mg/m2 at 4-week intervals. If no dose-limiting toxicity occurred, dosages were escalated by increments of 10 mg/m2 in subsequent cohorts. Originally, Doxil was administered over 60 min, but significant infusion reactions prompted longer infusion times of 4 h. Patients also received premedication with dexamethasone, ranitidine, and diphenhydramine 24 h before infusion, with ranitidine continued 24 h after infusion. Periodic blood samples were collected and plasma doxorubicin concentrations were quantified to characterize the pharmacokinetics of Doxil. Results: Between January 1997 and June 2000, 22 children ages 4-21 years with refractory tumors were treated with Doxil. Most patients had received one to five prior chemotherapy regimens, and all but five had prior radiotherapy (two had no prior therapy). Doxil was escalated to a dosage of 70 mg/m2. At that level, dose-limiting mucositis was seen during the first cycle in two of six patients, thus defining dose-limiting toxicity, and in one additional patient during a subsequent cycle. Grade 4 neutropenia lasting less than 7 days was documented in two of six patients. The dose-limiting toxicity among two of six patients at 70 mg/m2 was grade 3 mucositis during the first cycle of therapy. Painful desquamating dermatitis of the hands and feet, palmar-plantar erythrodysesthesia, occurred in six patients. In two of those patients, palmar-plantar erythrodysesthesia started as grade 1 and progressed to grade 2 during subsequent courses. Mean estimates of central volume of distribution, clearance, and elimination half-life were 1.45 liters/m2, 0.03 liter/h/m2, and 36.4 h, respectively. Conclusion: The maximum tolerated dose of Doxil administered every 4 weeks to pediatric patients was 60 mg/m2. The effect of Doxil on pediatric patients with malignancies remains to be determined and should be studied in pediatric Phase II trials.

UR - http://www.scopus.com/inward/record.url?scp=0036188460&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036188460&partnerID=8YFLogxK

M3 - Article

VL - 8

SP - 413

EP - 418

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 2

ER -